Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Telecon, January 13, 2012 - HPC Cord Blood


Submission Type: BLA    Submission ID: 125391/0    Office: OCTGT
Hematopoietic Progenitor Cells,Cord (HPC-C)
Clinimmune Labs
Telecon Date/Time: 13-January-2012 1:00 PM        Initiated by FDA? Yes
Telephone Number: -----(b)(4)-----
Communication Categorie(s):
CMC - Sterility Issues
Telecon Summary:
Sterility Issues
Ramani Sista
Joydeep Ghosh
Brian Freed
Sabine Stockinger
Linda Tapia
Michael Aubrey
Deborah Havens (Supervisor, Microbiology Lab)
Trans-BLA Group: No
 Related STNs: None
Related PMCs: None
Telecon Body:
Following introductions, Dr. Ghosh stated that this telecom was to further discuss the sterility validation issues, outlined in previous calls.
Regarding validation for robustness, FDA stated that since using a (b)(4) temperature may increase the minimum time of detection, the Sponsor may provide the following information in writing in lieu of conducting the test at -(b)(4)-. FDA asked the Sponsor to provide the following:
  • Plan of action in the event of machine failure
  • Temperature failure
FDA recommended the Sponsor to summarize their procedures in detail at -(b)(4)- and submit to application. 
Regarding ruggedness, FDA recommended the Sponsor to use (b)(4) lots of media at (b)(4) in triplicate for the (b)(4) microorganisms listed in the table of the word document provided to the Sponsor earlier.

Page Last Updated: 06/21/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English